Variability in the Prescription of Cholinesterase Inhibitors and Memantine

Abstract

Considerable variability in AD treatment has been detected. More consensus is needed to reduce variability in order to improve the quality of the pharmacotherapy for AD and assure equal treatment opportunities for every patient.